Product Name: PKCDSubtide
Product Number: PE-01BIS95
Size: 200 µg      Price:40.00
1 mg      $US80.00
5 mg      187.00
Peptide Name: PKCDSubtide

Product Use: For assaying the phosphotransferase activity of Protein-serine kinase C delta (UniProt ID Q05655).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: GLRRRGSFRRKG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1618.93 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: PKCD

Scientific Background: PKCd (PRKCD, PKC-delta) is a protein-serine/threonine kinase in the novel protein kinase C family. It is dependent on acidic phospholipids (e.g. phosphatidylserine) and diacylglycerol for full phosphotransferase activity, and does not require calcium. It is highly expressed and widely distributed in most tested human tissues, and is a major isoform of PKC expressed in hemopoietic cells. It is involved in promoting apoptosis, differentiation of cell types, cell growth, regulation of transcription factors, NFkB signalling induced by reactive oxygen species, and antigen presentation. PKCd is activated by phosphorylation at Y313, Y514, Y525, and S645. Phosphorylation of T507 increases phosphotransferase activity and induces degradation of PKC-delta. Phosphorylation of Y52, Y64, Y187, and Y567 inhibits phosphotransferase activity. Phosphatidylinositol is the most potent activator of PKCd. PKC delta is involved in fundamental cellular functions regulated by diacylglycerols, which is mimicked by phorbol esters. PKCd may be a tumour suppressor protein (TSP). PKCd negatively regulates cell proliferation in colon cell lines. It is also required for ErbB2-driven mammary gland tumourigenesis. Overexpression is seen in breast cancer and is associated with tamoxifen resistance. Reduced expression in MCF-7 cells is associated with a metastatic phenotype.